Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
1
FDAFDA Updates Updates and Developmentsand Developments
Maria Lourdes C. Santiago, MSc, MM Officer-in-Charge
Center for Drug Regulation and Research PAPPI’s 1st GMM 2013
26 July 2013
2
Presentation OutlinePresentation Outline
Regulatory Framework
Our Vision, Mission, Quality Policy
CDRR Organizational Structure
CDRR Strategies
Regulatory Updates
Accomplishments
Commitments for the 2nd sem 2013
Way Forward
3
Regulatory framework
Elements of regulatory framework to Elements of regulatory framework to assure quality and safety of drugs assure quality and safety of drugs
• Licensing/ Accreditation of establishments – GMP, GDP, GSP, GCP and GLP
• Pre-marketing assessment – of quality, safety and efficacy (for innovative medicines) and – quality + interchangeability (for generics)
• Post-marketing surveillance – SAFETY:
• Medicine safety monitoring (monitoring balance of benefits/risk of harm)
– QUALITY • Quality testing of samples • Continuous monitoring of compliance with GMP, GDP, GSP, etc.
4
Requirements for MA • Valid license to operate (LTO) as proof of compliance to
GMP, GDP and GSP
• Submission of registration dossier as described in the national guidelines and/or ASEAN Common Technical Documents (ACTD))/ICH CTD
– Analytical Validation
– ASEAN Stability Guidelines
– Process Validation
– Bioequivalence
– ASEAN Variation Guidelines
– ICH Safety and Efficacy Guidelines
• Representative Samples/Labeling materials – product information
5
PMS ACTIVITIES
– Pharmacovigilance Safety monitoring of drugs on the market for unexpected
health risks and informing the public of risks posed by
specific drugs and other health products;
– Monitoring, collecting, sampling and testing of
drugs
– Audits and inspection of manufacturers/
distributors/ retail outlets
– Consumer reporting of ADR
– Product recall / Administrative sanctions
6
7
Vision, Mission & Quality Policy
8
Our Vision, Mission and Quality Policy
VISION
To be an internationally recognized center of regulatory excellence safeguarding the
health of the Filipinos
MISSION
To ensure the safety, efficacy, purity
and quality of products we regulate
through effective implementation of the
national regulatory framework
consistent with international best
practice
Our highest commitment is to ensure the safety, efficacy and quality of health products. Toward this end,:
we commit to establish science based standards as basis for regulatory policies,
to continually improve and maintain our competence
to deliver quality public service with integrity
Quality Policy
9
CDRR Organizational
Structure
OFFICE OF THE CENTER OIC
LICENSING AND REGISTRATION
DIVISION
PRODUCT RESEARCH AND STANDARDS
DEVELOPMENT DIVISION
Manufacturers
Traders Licensing
Distributors/ Retail Outlets
Licensing
Pharma/ Human Drug Registration
STANDARD DEVELOPMENT
Section
PMS Section
CLINICAL RESEARCH
Section
CENTER FOR DRUG REGULATION AND RESEARCH
Veterinary Drug
Registration
Vaccine and Biologicals
Registration
Clinical Trial
Evaluation
10
11
Licensing and Registration Division
• Licensing (Initial Issuance /Amendments)
• In coordination with RFO
• Oversight function over Regional inspectors
including inspection of the establishments
• Evaluation and registration of human and
veterinary drugs
• Clinical and CMC
• Post approval changes
• Establishment and product verification and
certification
• Issuance of CPP and other clearances
12
Product Research and Standard Development
Division
• Conduct of research and development of
standards
• Development of strategies for PMS
(Identify all PMS activities)
• Compliance monitoring ( Analysis of field
data)
• Accreditation of CROs and other facilities
engaged in the conduct of clinical research
• GCP, GLP, GTP
• Oversight of clinical research
13
Other functions of the CenterOther functions of the Center
•Standards development including policies and
guidelines ( PPO)
•Provision of technical assistance in capacity
building of stakeholders (PPO)
•Attendance to ASEAN Harmonization or
international meetings (PPO)
•Quality Assurance - Development and
maintenance of Quality Management
System (PPO)
CDRR MANPOWER COMPLEMENTCDRR MANPOWER COMPLEMENT during transitionduring transition
Total no. of
CDRR
personnel
Permanent Contractual
74
T- 27
NT- 16
T- 27
NT- 4
14
15
List OF CDRR OfficersList OF CDRR Officers
Center OIC – Maria Lourdes C. Santiago LRD OIC – Melody Zamudio Licensing Supervisor - Evangeline Manalo Registration /Post Approval Changes Biotech derived: Grace Medina Veterinary: Edgar Calbitaza New Drug/Generics: Wenzel Asprec PAC/Amendments: Lisa Pajarillo CTU: Tito King PV: Lanette Querubin PRSDD OIC - Regina Obligacion
16
CDRR Strategies
CDRR Strategic Objectives
Significant changes have been introduced which aims to:
• provide earlier/timely access to quality medicines,
• reduce regulatory burden by streamlining some work processes
• increase time savings and
• enable greater operational efficiency
WITHOUT COMPROMISING SAFETY, EFFICACY AND QUALITY STANDARDS
17
CDRR Strategies
1. Work on improving the efficiency, clarity and transparency of the CDRR work process
– Introduce and implement the Good Regulatory Practice and Good Management Review Practice
3. Review and update the existing policies and regulations to align with the international standards
4. Draft new polices to keep abreast with the new and emerging technology in the field of drug development
18
CDRR Strategies 5. Advocate a robust yet flexible and risk based regulatory system that places an utmost priority on patient safety while enabling timely access to potentially new life- saving drugs and other quality generic drug products.
6. Enhance both the premarket and post market regulatory process in coordination with the FROO. Priority is given to drug products of higher risks (phased approach).
7. Develop a coordinated approach with the different FROOs and other government agencies on safety and quality issues with an immediate impact on patient safety through PMS and PV.
19
CDRR Strategies
8. Continuous re-training and re-tooling of all technical and administrative personnel to ensure consistency in the interpretation and implementation of the guidances
9. Establish closer collaboration with other DRAs to broaden our knowledge and strengthen the regulatory capabilities as we aim to be internationally recognized.
10. Regular communication/ dialogue with industry stakeholders to ensure transparency and smoother transition through quarterly “KAPIHAN AT TALAKAYAN SA FDA”
20
21
Regulatory Regulatory Updates: Updates:
DOH/FDA DOH/FDA Issuances Issuances
New Authorization Process
29 July 2013 22
Republic of the Philippines Department of Health
Food and Drug Administration
FDA Issuances
• FDA Memorandum Circular No. 2013-001 , Guidelines on the Submission of LTO and CPR Application with Electronic Copy (e-copy)
• FDA Memorandum Circular No. 2013-001-A, Amending FDA Memorandum Circular No. 2013-001
29 July 2013 23
Republic of the Philippines Department of Health
Food and Drug Administration
FDA Issuances • FDA Circular No. 2013-008 ADOPTION OF THE ASSOCIATION OF THE SOUTHEAST ASIAN NATIONS (ASEAN) POST-MARKETING ALERT SYSTEM (PMAS) FOR DEFECTIVE OR UNSAFE PROCESSED FOOD PRODUCTS, PHARMACEUTICAL PRODUCTS, TRADITIONAL MEDICINES AND HEALTH SUPPLEMENTS, AND COSMETIC AND HOUSEHOLD HAZARDOUS PRODUCTS AND DEVICES
This Circular provides for the adoption of PMAS as a national guideline for the surveillance of unsafe and defective processed food products, pharmaceutical products, traditional medicines and health supplements, cosmetics, and devices.
29 July 2013 24
Republic of the Philippines Department of Health
Food and Drug Administration
FDA Issuances
• FDA Circular No. 2013-004 POST MARKETING SURVEILLANCE (PMS) OF AUTHORIZED DRUG PRODUCTS This Circular sets the standards and requirements on PMS system
that defines the duties, responsibilities, and obligations of the
Market Authorization Holder (MAH) and the Qualified Persons in
Regulatory Affairs (QPIRA) in order to maintain the availability
and accessibility of their products in the market.
29 July 2013 25
Republic of the Philippines Department of Health
Food and Drug Administration
FDA Issuances • FDA Memorandum Circular No. 2013-004
QUALIFIED PERSON IN INDUSTRY (FOOD, DRUG,
COSMETIC, AND DEVICE) REGULATORY AFFAIRS (QPIRA) TRAINING-ACCREDITATION GUIDELINES This Memorandum Circular details the guidelines for the
training and accreditation of liaison officers and regulatory
affairs officers to ensure that the QPIRAs demonstrate
competence and professionalism in preparing and submitting
the correct and complete applications and dossiers.
29 July 2013 26
Republic of the Philippines Department of Health
Food and Drug Administration
FDA ISSUANCES
• CDRR Memorandum No. 0004, s. 2013 [Follow-ups, Technical Inquiries and Face-to-Face Interactions]
• FDA Memorandum Circular No. 2013-04 [Follow-up of Applications
• FDA Memorandum Circular No. 2013-019 [Decking Schedule of Drug Product Registration Applications ]
29 July 2013 27
CDRR Memorandum No. 003, s. 2013 Facilitation of Applications for Product Registration
1. Products to be manufactured exclusively for export ;
2. New drug products considered to be a major therapeutic advance ;
3. The first 5 products of a newly licensed establishment;
4. Products for government programs and projects ;
5. Imported prequalified vaccines
29 July 2013 28
FDA ISSUANCES
29 July 2013 29
• CDRR Memo Circular No. 0004, s. 2013
Follow-ups, Technical Inquiries and Face-to-Face
Interactions
• FDA Circular No. 2013-012 Validity of Generic
Labeling Exemption for Pharmaceutical Products
• FDA Memo Circular No. 2013-019 Decking
Schedule of Drug Product Registration
Applications
FDA ISSUANCE
FDA Circular No. 2013-0014
- List of Products Requiring Bioavailability/ Bioequivalence (BA/BE) Studies as Part of the Application for Marketing Authorization in Addition to Rifampicin and the 11 Products Listed in Bureau Circular No. 2006-008
30
FDA ISSUANCE
FDA Circular No. 2013-0014
- Expansion of the requirement of BE Studies to cover:
• BCS Class 4 drugs (low solubility, low permeability)
• BCS Class 2 drugs (low solubility, high permeability) not eligible for biowaiver
• Modified-release products for oral administration designed to act systemically
• Subsequent generic products after the patent of the innovator has expired (unless biowaiver can be supported)
31
FDA ISSUANCE
FDA Circular No. 2013-0014
- Certain drug products may avail of biowaiver based on the aqueous solubility and intestinal permeability of the API, and dissolution performance of the dosage form:
• BCS Class 1 drugs (high solubility, high permeability)
• BCS Class 2 drugs (low solubility, high permeability) with weak acidic properties
• BCS Class 3 drugs (high solubility, low permeability)
32
DOH ISSUANCE
Administrative Order No. 2012-024
- Amendment of A.O. No. 50 s. 2001 Covering Fees and Charges for Accreditation of Bioequivalence Testing Centers and Private Testing Laboratories, as well as, Audits and Inspections
• Bioequivalence testing center accreditation – PHP 20,000 per year [from PHP 10,000 per year]
• GCP/GLP audit of bioequivalence testing center – PHP 15,000 + transportation cost (with per diem of each inspector if facility is outside Metro Manila) [from PHP 5,000]
33
FDA ISSUANCES • FDA MEMO CIRCULAR NO. 2013-023
Conversion to Electronic Copy of All Registered Drug Products’ Dossier
• FDA MEMO CIRCULAR NO. 2013-025
Transfer of Advertisement and Promotion Functions from the Legal Services Support Center to the Other Centers of the FDA
• FDA Memo Circular No. 2013-028 General Guidelines on the Promo Permit Applications and for Other Purposes
29 July 2013 34
DOH/FDA ISSUANCE
• AO 2013- 0012
Rules and Regulations Governing the Accreditation of Health Facilities in Human Stem Cell and Cell Based or Cellular Therapies in the Philippines
• FDA CIRCULAR NO. 2013-017
Registration of Human Stem Cell-Based Products
29 July 2013 35
DOH ISSUANCE
• AO 2013-0021 Adoption of the Association of
Southeast Asian Nations (ASEAN) Common
Technical Dossier (ACTD) and Common
Technical Requirements (ACTR) for the
Registration of Pharmaceutical Products for
Human Use
– Published in the newspaper 20 July 2013
– Full implementation by 06 August 2013
29 July 2013 36
37
AccomplishmentsAccomplishments
Accomplishments
• Harnessing ICT to Improve Regulatory Efficiency
– Use of FDA E-mail System (Zimbra)
– Upgrading of FDA Website (fda.gov.ph)
Uploading of the list of applications for initial registration
Decking schedule made available
List of registered products (to be further enhanced)
29 July 2013 38
New FDA Website
29 July 2013 39
eReport
29 July 2013 40
Accomplishments
• Launching of FDA Academy – FDA platform for training/retooling FDA Employees,
QPIRA and industry – FDA Internship Program
• QPIRA (Qualified Personnel in Regulatory Affairs) – To ensure correct and complete submission of
marketing authorization dossier, increase work efficiency and improve turnaround time
– To improve information dissemination and communication
– To facilitate e-documentation of all transactions in the future
29 July 2013 41
Accomplishments
• Initiate BA/BE Studies Capability Building
– BA/BE capability building for Gov’t and Private Hospitals
– Ensure interchangeability
– Philippines as Clinical Trial Center for new drugs
29 July 2013 42
Field Regulatory Operations Office Re-tooling
• Regional FRO Clusters
• Regional Field Office (RFO)
– Administrative Division
– Licensing, Inspection and Compliance Division
• Regional Enforcement Unit (REU)
• Satellite Laboratories
– Davao and Cebu
29 July 2013 43
44
22ndnd semsem 20132013 CommittmentsCommittments
2nd sem Commitments 1. To continue what has been started especially in the review
and updating of regulation ensuring its alignment with the international standards and practices – Regulation on Biosimilars
– Regulation on blood and blood products
– Mexico Principle Declaration (Ethical practices)
– Revision of AO 67 (1989) –Registration guidelines Human and Veterinary drug products
– Good Distribution Practice and Good Storage Practice
– Revision of AO 55 (1988), 85 and 99 (1990 )- Labeling requirements
– Revision of AO 56 (1989) Licensing of establishments
2. To act on all incoming requests (licensing/ registration application and post approval changes within the committed TOT
45
2nd sem Commitments
3. To intensify post market surveillance following the risk based approach
• Inspection and product quality monitoring
• Pharmacovigilance
4. Together with PPO, CDRR will conduct training for the:
– Qualified Persons in the Industry Regulatory Affairs (QPIRA) in of Registration of Drug Products
– Licensing of Establishments -
46
47
The way forwardThe way forward
Risk Based Approach to: Drug Product Evaluation
GMP Inspection and Certification
Quality Control Testing
Post Market Surveillance
Upgrading of Testing Facilities Lot Release of Imported Vaccines including laboratory
testing
Quality control testing of Biosimilars eg EPO
Determination of contaminants and other impurities
48
WAY FORWARD: REVIEW WORK PROCESSES
WAY FORWARD:
• Market-Driven, Demand-Driven Price Reduction – Drug Outlet Digital Cartography – Google Map: Location of all outlets and Price of
Essential Drugs – Patient can choose: consider the distance from drug
outlet and price – Reduction of Drug Price: lower selling price due to
competition and increase market share (ICT)
• Alignment with NCPAM – Botika ng Barangay – Training of pharm assistanst to dispense health
products in low risks drug outlets (under discussion with PRC/Pharmacist)
29 July 2013 49
• Greater Focus on Collaboration with other NDRAs
Discussion/Talks with
USFDA/Singapore/KFDA/Malaysia
Joint GMP Audits through JSC
Joint/Collaboration - Evaluation of Dossiers
• PICS Accession
50
WAY FORWARD: INTERNATIONAL COLLABORATION/CONVERGENCE
ANNOUNCEMENT
• Forum for Consumer Reporting System - “Bringing Pharmacovigilance Closer to You”
30 July 2013, 1:00-5:00 pm
Vivere Hotel
29 July 2013 51
29 July 2013 52
53
THANK YOUTHANK YOU